Figure A1.

Correlation between baseline CD4+ T-cell counts and hepatitis B virus (HBV) DNA decline after initiation of ADV treatment. Data from HIV/HBV coinfected subjects are indicated as circles and data from HBV monoinfected subjects are indicated as squares. (Panel A) Relationship between baseline HBV DNA levels and baseline CD4 T-cell counts. (Panel B) Relationship between HBV DNA decline (0–2 weeks) after initiation of ADV therapy. The early phase of HBV viral decay (0–2 weeks) was faster in the 5 monoinfected individuals (−1.5 to −4.0 log copies/mL), whereas it was variable among the HIV/HBV coinfected (−0.5 to −3.5 log copies/mL). (Panel C) Relationship between HBV DNA decline (after week 2 to week 4) after initiation of ADV therapy. Baseline CD4+ T cell counts correlated positively with slope decline of HBV in all patients (r = 0.8, P < .001), particularly in coinfected patients (r = 0.65, P < .05). Coinfected patients with CD4+ T-cell counts less than 600 cells/mm³ had a much lower HBV viral load decline than those with CD4+ T-cell counts >600 cells/mm³ (P < .04). (Panel D) Relationship between baseline CD4 T-cell counts and HBV DNA levels at 96 weeks. HBV DNA levels at 96 weeks after initiation of therapy were lower in the HBV monoinfected subjects. Subjects with higher baseline CD4 T-cell counts had lower HBV DNA levels regardless of HIV serostatus.